Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 3.29% | -0.35% | 1.01% | 5.67% | 18.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.29% | -0.35% | 1.01% | 5.67% | 18.53% |
| Cost of Revenue | -6.72% | -57.54% | -52.66% | -39.88% | -12.04% |
| Gross Profit | 5.71% | 19.14% | 21.71% | 23.03% | 29.38% |
| SG&A Expenses | 6.39% | 1.37% | 2.29% | 11.26% | 20.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -183.66% | -19,180.00% | -1,662.50% | -682.76% | -39.92% |
| Total Operating Expenses | 1.72% | -17.53% | -16.87% | -5.58% | 10.38% |
| Operating Income | 9.47% | 93.54% | 133.51% | 74.52% | 66.91% |
| Income Before Tax | 175.96% | 524.31% | 429.34% | 418.86% | 1,043.40% |
| Income Tax Expenses | 218.43% | 191.44% | 79.93% | -91.19% | -108.42% |
| Earnings from Continuing Operations | 81.08% | 188.85% | 593.84% | 544.57% | 2,762.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -20.00% | -60.00% | -50.00% | 0.00% | -66.67% |
| Net Income | 81.17% | 189.16% | 591.78% | 542.52% | 2,834.82% |
| EBIT | 9.47% | 93.54% | 133.51% | 74.52% | 66.91% |
| EBITDA | 3.57% | 52.77% | 45.39% | 30.36% | 30.36% |
| EPS Basic | 81.06% | 188.98% | 569.77% | 560.23% | 657.10% |
| Normalized Basic EPS | 10.55% | 114.17% | 177.70% | 95.06% | 78.51% |
| EPS Diluted | 81.27% | 190.43% | 566.37% | 557.64% | 679.67% |
| Normalized Diluted EPS | 10.53% | 113.43% | 176.68% | 94.35% | 77.66% |
| Average Basic Shares Outstanding | 0.05% | 0.08% | 0.91% | 4.95% | 9.30% |
| Average Diluted Shares Outstanding | 0.03% | 0.19% | 1.20% | 5.34% | 9.84% |
| Dividend Per Share | 0.00% | 0.00% | 0.00% | 1.05% | 1.05% |
| Payout Ratio | -0.43% | -0.65% | 1.21% | 1.23% | -0.96% |